Low-Dose Naltrexone Presents New Options for Patients with Inflammatory, Autoimmune Diseases

Video

Sebastian Denison, RPh, BScPharm, said new developments are constantly being published for the use of low-dose naltrexone in patients with inflammatory and autoimmune diseases.

In an interview at the Pharmacy Development Services 2022 conference, Sebastian Denison, RPh, BScPharm, said new developments are constantly being published for the use of low-dose naltrexone in patients with inflammatory and autoimmune diseases.

Traditionally used for patients with alcoholism or other forms of addiction, Denison said there is a growing body of case studies and research into the use of naltrexone for other treatments. Whereas the patented dosage is a 50 mg capsule, research is ongoing into the use of much smaller dosages. Denison also discussed the mechanism of action for naltrexone, how the evidence for naltrexone may differ from other bodies of research, and some adverse events that pharmacists should be aware of.

Related Videos
Female Pharmacist Holding Tablet PC - Image credit: Tyler Olson | stock.adobe.com
pain management palliative care/Image Credits: © Aleksej - stock.adobe.com
African American male pharmacist using digital tablet during inventory in pharmacy - Image credit: sofiko14 | stock.adobe.com
palliative and hospice care/ Image Credits: © David Pereiras - stock.adobe.com
Young woman using smart phone,Social media concept. - Image credit: Urupong | stock.adobe.com
multiple myeloma clinical trial daratumumab/ Image Credits: © Dragana Gordic - stock.adobe.com
multiple myeloma clinical trial/Image Credits: © Studio Romantic - stock.adobe.com
3d rendered illustration of lung cancer 3D illustration - Image credit:  appledesign | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.